The Hol Picture

The treatment of behavioral health conditions has historically been challenging. Despite the prevalent use of the DSM-V in clinical settings, clinicians lack a detailed and standardized vocabulary to discuss these conditions. This is due to a range of factors, from wide differences in disease presentation to stigma surrounding mental health conditions. The lack of standardized vocabulary has led to a subjective approach in treating these conditions, with each clinician relying on his or her own experience.

However, as more and more patients who are treated for behavioral health conditions are documented within an electronic health record (EHR) system, researchers now have a valuable tool for studying and improving the treatment of behavioral health conditions. By bringing together vast quantities of real-world data to understand how care and treatment are delivered in clinical practice, we can start building a set of standard definitions and objective measures for mental health conditions.

This is why we have created the NeuroBlu Database, in which we have extracted and organized EHR data from behavioral health clinics across the U.S. Our NeuroBlu data has thus far been leveraged by 5 of the top 15 biopharmaceutical companies with a behavioral health pipeline. These companies can benefit greatly from EHR-derived real-world data, particularly in the areas of research and development, medical affairs, and health economics and outcomes research (HEOR).

The HM Treasury in the United Kingdom recently announced an exciting and truly forward-looking initiative for healthcare: a package of government funding, called the Life Sci for Growth package, to fuel research and bring treatments to patients faster. There are many impressive projects being funded, from clinical trial improvements to preparation efforts for future public health emergencies. 

Imagine that you are a therapist seeing a new patient for the first time. The patient says that while she has no history of clinical depression, she has been feeling really sad lately and has lost interest in the things she normally enjoys, such as cooking and creating new recipes. 

When you start to ask questions, however, you begin to uncover the factors that may be impacting what your patient is currently experiencing. She tells you she has recently moved across the country and has had trouble finding a new community where she feels connected. Because she feels so sad most of the time, she has stopped calling anyone from her previous home, telling you that she “doesn’t want to bring them down.” You hypothesize that the recent drastic changes in her environment may be contributing to the symptoms of depression she describes.

Today, Digital Health New York (DHNY) released its Q1 Healthcare Innovation Report, of which we were honored to be a part.

This year at the American Society of Clinical Psychopharmacology’s annual conference, I had the privilege to organize and chair a panel discussion on challenges and opportunities in leveraging real-world evidence to inform the development of new treatments in behavioral health.

On Clinical Trials Day, we recognize an important part of the healthcare infrastructure: the studies that rigorously evaluate new treatments to determine which will be effective and safe for improving patient health. Through the conventional process of assessment, the treatments that succeed will go on to regulatory approval and will be marketed to patients and their providers.